DIA Bioventure Day

Is the current Bioventure paradigm delivering return for patients and investors? This is the key question to be addressed by stakeholders from the funding, and from the innovating side.

Back to Agenda

Hepatitis C: Expensive Cure Versus Life-Long Suffering and Health Care Expenses

Session Chair(s)

Helga Ruebsamen-Schaeff

Chair of the Board

AiCuris, Germany

Since HCV increases the risk of liver cirrhosis and liver cancer tremendously, it was a great achievement that the industry was able, only about 24 years after the discovery of the virus to develop drugs which cure the disease. Yet, the prices which were asked for such curative drugs were heavily criticized. The panel will discuss how a fair price for a curative treatment can be defined and how it can be avoided that price cuts make an indication area so unattractive that nearly no new drugs are being developed any more, as is the case for antibiotics.

Have an account?

DIA Bioventure Day

Hepatitis C: Expensive Cure Versus Life-Long Suffering and Health Care Expenses

Session Chair(s)

Helga Ruebsamen-Schaeff

Be informed and stay engaged.